Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2018

Open Access 01.12.2017 | Original Article

EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems

verfasst von: Andres Kaalep, Terez Sera, Wim Oyen, Bernd J. Krause, Arturo Chiti, Yan Liu, Ronald Boellaard

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

From 2010 until July 2016, the EANM Research Ltd. (EARL) FDG-PET/CT accreditation program has collected over 2500 phantom datasets from approximately 200 systems and 150 imaging sites worldwide. The objective of this study is to report the findings and impact of the accreditation program on the participating PET/CT systems.

Methods

To obtain and maintain EARL accredited status, sites were required to complete and submit two phantom scans - calibration quality control (CalQC), using a uniform cylindrical phantom and image quality control (IQQC), using a NEMA NU2–2007 body phantom. Average volumetric SUV bias and SUV recovery coefficients (RC) were calculated and the data evaluated on the basis of quality control (QC) type, approval status, PET/CT system manufacturer and submission order.

Results

SUV bias in 5% (n = 96) of all CalQC submissions (n = 1816) exceeded 10%. After corrective actions following EARL feedback, sites achieved 100% compliance within EARL specifications. 30% (n = 1381) of SUVmean and 23% (n = 1095) of SUVmax sphere recoveries from IQQC submissions failed to meet EARL accreditation criteria while after accreditation, failure rate decreased to 12% (n = 360) and 9% (n = 254), respectively. Most systems demonstrated longitudinal SUV bias reproducibility within ±5%, while RC values remained stable and generally within ±10% for the four largest and ±20% for the two smallest spheres.

Conclusions

Regardless of manufacturer or model, all investigated systems are able to comply with the EARL specifications. Within the EARL accreditation program, gross PET/CT calibration errors are successfully identified and longitudinal variability in PET/CT performances reduced. The program demonstrates that a harmonising accreditation procedure is feasible and achievable.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.CrossRefPubMed Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.CrossRefPubMed
2.
Zurück zum Zitat de Geus-Oei L-F, van der Heijden HFM, Corstens FHM, Oyen WJG. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654–64.CrossRefPubMed de Geus-Oei L-F, van der Heijden HFM, Corstens FHM, Oyen WJG. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654–64.CrossRefPubMed
3.
Zurück zum Zitat Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med. 2006;47:1059–66.PubMed Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med. 2006;47:1059–66.PubMed
4.
Zurück zum Zitat Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083.CrossRefPubMed Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083.CrossRefPubMed
5.
Zurück zum Zitat Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst. 2007;99:1753–67.CrossRefPubMed Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst. 2007;99:1753–67.CrossRefPubMed
6.
Zurück zum Zitat Lv Y-L, Yuan D-M, Wang K, Miao X-H, Qian Q, Wei S-Z, et al. Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J. Thorac. Oncol. International Association for the Study of. Lung Cancer. 2011;6:1350–8. Lv Y-L, Yuan D-M, Wang K, Miao X-H, Qian Q, Wei S-Z, et al. Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J. Thorac. Oncol. International Association for the Study of. Lung Cancer. 2011;6:1350–8.
7.
Zurück zum Zitat Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:463–71.CrossRefPubMed Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:463–71.CrossRefPubMed
8.
Zurück zum Zitat Hicks RJ, Kalff V, Macmanus MP, Ware RE, Mckenzie AF, Matthews JP, et al. The utility of F-FDG PET for suspected recurrent non – small cell lung cancer after potentially curative Therapy : impact on management and prognostic stratification. J Nucl Med. 2001;42:10–21. Hicks RJ, Kalff V, Macmanus MP, Ware RE, Mckenzie AF, Matthews JP, et al. The utility of F-FDG PET for suspected recurrent non – small cell lung cancer after potentially curative Therapy : impact on management and prognostic stratification. J Nucl Med. 2001;42:10–21.
9.
Zurück zum Zitat Dijkman BG, Schuurbiers OCJ, Vriens D, Looijen-Salamon M, Bussink J, Timmer-Bonte JNH, et al. The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. Eur J Nucl Med Mol Imaging. Berlin/Heidelberg: Springer-Verlag. 2010;37:2037–47.CrossRefPubMedPubMedCentral Dijkman BG, Schuurbiers OCJ, Vriens D, Looijen-Salamon M, Bussink J, Timmer-Bonte JNH, et al. The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. Eur J Nucl Med Mol Imaging. Berlin/Heidelberg: Springer-Verlag. 2010;37:2037–47.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Hellwig D, Graeter TP, Ukena D, Groeschel A, Sybrecht GW, Schaefers HJ, et al. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med. 2007;48:1761–6.CrossRefPubMed Hellwig D, Graeter TP, Ukena D, Groeschel A, Sybrecht GW, Schaefers HJ, et al. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med. 2007;48:1761–6.CrossRefPubMed
11.
Zurück zum Zitat Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong C-YO. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37:691–8.CrossRefPubMed Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong C-YO. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37:691–8.CrossRefPubMed
12.
Zurück zum Zitat Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27–38.CrossRefPubMed Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27–38.CrossRefPubMed
13.
Zurück zum Zitat Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983–95.PubMed Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983–95.PubMed
14.
Zurück zum Zitat Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009;50:31S–42.CrossRefPubMed Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009;50:31S–42.CrossRefPubMed
15.
Zurück zum Zitat Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med United States. 2006;57:99–118.CrossRef Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med United States. 2006;57:99–118.CrossRef
16.
Zurück zum Zitat Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov England. 2003;2:566–80.CrossRef Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov England. 2003;2:566–80.CrossRef
18.
Zurück zum Zitat Bengtsson T, Hicks RJ, Peterson A, Port RE. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. J Nucl Med. 2012;53:530–7.CrossRefPubMed Bengtsson T, Hicks RJ, Peterson A, Port RE. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. J Nucl Med. 2012;53:530–7.CrossRefPubMed
19.
Zurück zum Zitat Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628.CrossRefPubMed Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628.CrossRefPubMed
20.
Zurück zum Zitat Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4.PubMed Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4.PubMed
21.
Zurück zum Zitat Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol United States. 2003;21:2651–7.CrossRef Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol United States. 2003;21:2651–7.CrossRef
23.
Zurück zum Zitat Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol United States. 2010;195:310–20.CrossRef Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol United States. 2010;195:310–20.CrossRef
24.
Zurück zum Zitat Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S–20S.CrossRefPubMed Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S–20S.CrossRefPubMed
25.
Zurück zum Zitat Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR United States. 2010;31:496–505.CrossRef Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR United States. 2010;31:496–505.CrossRef
26.
Zurück zum Zitat Fahey FH, Kinahan PE, Doot RK, Kocak M, Thurston H, Poussaint TY. Variability in PET quantitation within a multicenter consortium. Med Phys United States. 2010;37:3660–6. Fahey FH, Kinahan PE, Doot RK, Kocak M, Thurston H, Poussaint TY. Variability in PET quantitation within a multicenter consortium. Med Phys United States. 2010;37:3660–6.
27.
Zurück zum Zitat Beyer T, Czernin J, Freudenberg LS. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. J Nucl Med United States. 2011;52:303–10.CrossRef Beyer T, Czernin J, Freudenberg LS. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. J Nucl Med United States. 2011;52:303–10.CrossRef
28.
Zurück zum Zitat Graham MM, Badawi RD, Wahl RL. Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med. 2011;52:311–7.CrossRefPubMedPubMedCentral Graham MM, Badawi RD, Wahl RL. Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med. 2011;52:311–7.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Hristova I, Boellaard R, Vogel W, Mottaghy F, Marreaud S, Collette S, et al. Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. Eur J Nucl Med Mol Imaging. 2015;42:848–57.CrossRefPubMedPubMedCentral Hristova I, Boellaard R, Vogel W, Mottaghy F, Marreaud S, Collette S, et al. Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. Eur J Nucl Med Mol Imaging. 2015;42:848–57.CrossRefPubMedPubMedCentral
30.
31.
Zurück zum Zitat Buckler AJ, Boellaard R. Standardization of quantitative imaging: the time is right, and 18F-FDG PET/CT is a good place to start. J Nucl Med. 2011;52:171–2.CrossRefPubMed Buckler AJ, Boellaard R. Standardization of quantitative imaging: the time is right, and 18F-FDG PET/CT is a good place to start. J Nucl Med. 2011;52:171–2.CrossRefPubMed
32.
Zurück zum Zitat Sunderland JJ, Christian PE, Quantitative PET. CT scanner performance characterization based upon the Society of Nuclear Medicine and Molecular Imaging clinical trials network oncology clinical simulator phantom. J Nucl Med. 2015;56:145–52.CrossRefPubMed Sunderland JJ, Christian PE, Quantitative PET. CT scanner performance characterization based upon the Society of Nuclear Medicine and Molecular Imaging clinical trials network oncology clinical simulator phantom. J Nucl Med. 2015;56:145–52.CrossRefPubMed
33.
Zurück zum Zitat Rausch I, Cal-González J, Dapra D, Gallowitsch HJ, Lind P, Beyer T, et al. Performance evaluation of the biograph mCT flow PET/CT system according to the NEMA NU2-2012 standard. EJNMMI Phys. 2015;2:26.CrossRefPubMedPubMedCentral Rausch I, Cal-González J, Dapra D, Gallowitsch HJ, Lind P, Beyer T, et al. Performance evaluation of the biograph mCT flow PET/CT system according to the NEMA NU2-2012 standard. EJNMMI Phys. 2015;2:26.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96.CrossRefPubMedPubMedCentral Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014;42:328–54.CrossRefPubMedPubMedCentral Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014;42:328–54.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.PubMed Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.PubMed
37.
Zurück zum Zitat Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, et al. Summary of the UPICT protocol for 18F-FDG PET/CT imaging in oncology clinical trials. J Nucl Med. 2015;56:955–61.CrossRefPubMedPubMedCentral Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, et al. Summary of the UPICT protocol for 18F-FDG PET/CT imaging in oncology clinical trials. J Nucl Med. 2015;56:955–61.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Makris NE, Huisman MC, Kinahan PE, Lammertsma AA, Boellaard R. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging. 2013;40:1507–15.CrossRefPubMed Makris NE, Huisman MC, Kinahan PE, Lammertsma AA, Boellaard R. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging. 2013;40:1507–15.CrossRefPubMed
39.
Zurück zum Zitat Scheuermann JS, Saffer JR, Karp JS, Levering AM, Siegel A. Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med. 2010;50:1187–93.CrossRef Scheuermann JS, Saffer JR, Karp JS, Levering AM, Siegel A. Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med. 2010;50:1187–93.CrossRef
40.
Zurück zum Zitat Kinahan P, Wahl R, Shao L, Frank R, Perlman E. The QIBA profile for quantitative FDG-PET/CT oncology imaging. J Nucl Med. 2014;55:1520. Kinahan P, Wahl R, Shao L, Frank R, Perlman E. The QIBA profile for quantitative FDG-PET/CT oncology imaging. J Nucl Med. 2014;55:1520.
43.
Zurück zum Zitat Geworski L, Knoop BO, de Wit M, Ivancevic V, Bares R, Munz DL. Multicenter comparison of calibration and cross calibration of PET scanners. J Nucl Med. 2002;43:635–9.PubMed Geworski L, Knoop BO, de Wit M, Ivancevic V, Bares R, Munz DL. Multicenter comparison of calibration and cross calibration of PET scanners. J Nucl Med. 2002;43:635–9.PubMed
Metadaten
Titel
EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems
verfasst von
Andres Kaalep
Terez Sera
Wim Oyen
Bernd J. Krause
Arturo Chiti
Yan Liu
Ronald Boellaard
Publikationsdatum
01.12.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3853-7

Weitere Artikel der Ausgabe 3/2018

European Journal of Nuclear Medicine and Molecular Imaging 3/2018 Zur Ausgabe